

# Robert A Kyle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9461738/publications.pdf>

Version: 2024-02-01

482  
papers

38,733  
citations

7551

77  
h-index

3021

188  
g-index

488  
all docs

488  
docs citations

488  
times ranked

18083  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.	0.8	2,404
3	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.	0.6	2,022
4	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2003, 78, 21-33.	1.4	1,904
5	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
6	A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2002, 346, 564-569.	13.9	1,304
7	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2004, 351, 1860-1873.	13.9	1,291
8	Prevalence of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2006, 354, 1362-1369.	13.9	1,135
9	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. <i>Journal of Clinical Oncology</i> , 2012, 30, 989-995.	0.8	837
10	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17046.	18.1	812
11	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 3751-3757.	0.8	774
12	Multiple myeloma. <i>Blood</i> , 2008, 111, 2962-2972.	0.6	759
13	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 2582-2590.	13.9	740
14	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
15	A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. <i>New England Journal of Medicine</i> , 1997, 336, 1202-1207.	13.9	656
16	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2005, 106, 812-817.	0.6	557
17	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1014-1020.	1.2	460
18	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. <i>Blood</i> , 2012, 120, 4292-4295.	0.6	447

#	ARTICLE	IF	CITATIONS
19	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
20	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2018, 378, 241-249.	13.9	392
21	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	0.6	377
22	Diagnosis of monoclonal gammopathy of renal significance. <i>Kidney International</i> , 2015, 87, 698-711.	2.6	339
23	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	4.1	330
24	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-1424.	0.6	317
25	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. <i>Lancet</i> , 2010, 375, 1721-1728.	6.3	313
26	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	0.6	300
27	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2003, 102, 3759-3764.	0.6	279
28	Screening Panels for Detection of Monoclonal Gammopathies. <i>Clinical Chemistry</i> , 2009, 55, 1517-1522.	1.5	268
29	How I treat monoclonal gammopathy of renal significance (MGRS). <i>Blood</i> , 2013, 122, 3583-3590.	0.6	259
30	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
31	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 926-933.	1.4	240
32	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006, 107, 3378-3383.	0.6	230
33	Neuropathy associated with monoclonal gammopathies of undetermined significance. <i>Annals of Neurology</i> , 1991, 30, 54-61.	2.8	219
34	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	0.8	193
35	Monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2006, 134, 573-589.	1.2	191
36	Amyloidosis: a convoluted story. <i>British Journal of Haematology</i> , 2001, 114, 529-538.	1.2	186

#	ARTICLE	IF	CITATIONS
37	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999, 93, 1062-1066.	0.6	180
38	Incidence of Monoclonal Proteins in a Minnesota Community With a Cluster of Multiple Myeloma. <i>Blood</i> , 1972, 40, 719-724.	0.6	179
39	Incidence of multiple myeloma in Olmsted County, Minnesota. <i>Cancer</i> , 2004, 101, 2667-2674.	2.0	178
40	Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years. <i>British Journal of Haematology</i> , 1996, 93, 345-351.	1.2	177
41	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. <i>Blood</i> , 2018, 132, 1478-1485.	0.6	173
42	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
43	Plasma cell leukemia: An evaluation of response to therapy. <i>American Journal of Medicine</i> , 1987, 83, 1062-1068.	0.6	164
44	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	1.4	164
45	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
46	Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. <i>American Journal of Medicine</i> , 1985, 79, 708-716.	0.6	159
47	Factor-X deficiency in amyloidosis: A critical review. <i>American Journal of Hematology</i> , 1981, 11, 443-450.	2.0	151
48	Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 793-798.	0.8	148
49	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. <i>Blood</i> , 2010, 116, 5126-5129.	0.6	146
50	Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. <i>American Journal of Cardiology</i> , 1985, 55, 1645.	0.7	136
51	Treatment of Multiple Myeloma: A Comprehensive Review. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 278-288.	1.4	135
52	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2016, 62, 1334-1344.	1.5	122
53	Primary Localized Amyloidosis of the Urinary Bladder: A Case Series of 31 Patients. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1264-1268.	1.4	119
54	Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. <i>Clinical Chemistry</i> , 2002, 48, 655-657.	1.5	115

#	ARTICLE	IF	CITATIONS
55	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	1.4	115
56	Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood, 2012, 119, 4462-4466.	0.6	113
57	Guidelines for Clinical and Laboratory Evaluation of Patients With Monoclonal Gammopathies. Archives of Pathology and Laboratory Medicine, 1999, 123, 106-107.	1.2	113
58	Factor X Deficiency in Primary Amyloidosis. New England Journal of Medicine, 1979, 301, 1050-1051.	13.9	112
59	Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2014, 113, 1723-1727.	0.7	112
60	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	0.6	111
61	Monoclonal gammopathies of undetermined significance: a review. Immunological Reviews, 2003, 194, 112-139.	2.8	110
62	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
63	"Primary" Systemic Amyloidosis and Myeloma. Archives of Internal Medicine, 1961, 107, 344.	4.3	109
64	Epidemiology of the plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2007, 20, 637-664.	0.7	109
65	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	3.3	108
66	A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry, 1985, 6, 506-512.	1.8	107
67	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	1.4	106
68	Primary systemic amyloidosis with delayed progression to multiple myeloma. , 1998, 82, 1501-1505.		105
69	Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clinic Proceedings, 2010, 85, 945-948.	1.4	105
70	Multiple Myeloma in Young Patients: Clinical Presentation and Treatment Approach. Leukemia and Lymphoma, 1998, 30, 493-501.	0.6	100
71	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology, 2007, 139, 730-743.	1.2	98
72	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1.	2.0	98

#	ARTICLE	IF	CITATIONS
73	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	1.2	95
74	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1071-1079.	1.4	94
75	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
76	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. <i>British Journal of Haematology</i> , 1994, 87, 266-272.	1.2	89
77	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	1.4	87
78	A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union. <i>Science</i> , 2014, 343, 656-661.	6.0	85
79	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 812-818.	0.8	85
80	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
81	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 262-262.	0.8	77
82	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76
83	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
84	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. <i>American Journal of Hematology</i> , 2010, 85, 171-173.	2.0	75
85	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
86	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
87	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
88	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. <i>Cancer</i> , 1993, 72, 108-113.	2.0	71
89	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. <i>Liver Transplantation</i> , 1996, 2, 375-382.	1.9	71
90	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71

#	ARTICLE	IF	CITATIONS
91	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
92	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. <i>British Journal of Haematology</i> , 1998, 101, 296-301.	1.2	70
93	Amyloid Localized to Tenosynovium at Carpal Tunnel Release: <i>Immunohistochemical Identification of Amyloid Type</i> . <i>American Journal of Clinical Pathology</i> , 1992, 97, 250-253.	0.4	68
94	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
95	Presence of an Abnormal Serum Free Light Ratio Is an Independent Risk Factor for Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS).. <i>Blood</i> , 2004, 104, 3647-3647.	0.6	66
96	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	0.8	64
97	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
98	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
99	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
100	Amyloid Localized to Tenosynovium at Carpal Tunnel Release: Natural History of 124 Cases. <i>American Journal of Clinical Pathology</i> , 1989, 91, 393-397.	0.4	62
101	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
102	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001, 68, 269-275.	2.0	61
103	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	1.2	61
104	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997, 90, 340-345.	0.6	59
105	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
106	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
107	Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays. <i>Clinical Chemistry</i> , 2015, 61, 360-367.	1.5	57
108	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57

#	ARTICLE	IF	CITATIONS
109	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
110	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Blood Cancer Journal</i> , 2019, 9, 102.	2.8	57
111	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016, 6, 380.	0.6	56
112	Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). , 1997, 56, 288-293.		54
113	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , 2019, 9, 27.	2.8	53
114	Cranial neuropathy associated with primary amyloidosis. <i>Annals of Neurology</i> , 1991, 29, 451-454.	2.8	52
115	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	1.3	51
116	Orthostatic Hypotension as a Clue to Primary Systemic Amyloidosis. <i>Circulation</i> , 1966, 34, 883-888.	1.6	50
117	IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 17-18.	1.4	50
118	Clinical course and prognosis of non-secreting multiple myeloma. <i>European Journal of Haematology</i> , 2015, 95, 57-64.	1.1	50
119	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	0.6	50
120	Identification of monoclonal proteins in serum: A quantitative comparison of acetate, agarose gel, and capillary electrophoresis. <i>Electrophoresis</i> , 1997, 18, 1775-1780.	1.3	49
121	Chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 1998, 103, 704-710.	1.2	49
122	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1093-1113.	0.9	49
123	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
124	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
125	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
126	Î¼-heavy chain disease: Presentation as a benign monoclonal gammopathy. <i>American Journal of Hematology</i> , 1992, 40, 56-60.	2.0	43



#	ARTICLE	IF	CITATIONS
127	Primary Localized Amyloidosis of The bladder:: Experience With Dimethyl Sulfoxide Therapy. Journal of Urology, 2002, 168, 1018-1020.	0.2	43
128	Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma and Myeloma, 2005, 6, 102-114.	1.4	43
129	Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	1.4	43
130	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clinical Biochemistry, 2018, 51, 38-47.	0.8	43
131	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
132	Monoclonal Proteins in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 1987, 87, 385-388.	0.4	41
133	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	2.5	41
134	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	1.2	41
135	Clinical course of light-chain smoldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematology, the, 2014, 1, e28-e36.	2.2	40
136	Tenâ€“year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	1.2	40
137	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
138	Computed tomography for diagnosis of hepatic rupture in primary systemic amyloidosis. American Journal of Hematology, 1991, 37, 194-196.	2.0	38
139	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	2.0	38
140	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.2	38
141	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	2.8	38
142	"Intermediate" Cell Types and Mixed Cell Proliferation in Multiple Myeloma: Electron Microscopic Observations. Blood, 1966, 27, 212-226.	0.6	37
143	Enhancing the Râ€“ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
144	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	0.6	36

#	ARTICLE	IF	CITATIONS
145	Progress in Myeloma – A Monoclonal Breakthrough. <i>New England Journal of Medicine</i> , 2016, 375, 1390-1392.	13.9	36
146	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
147	MONOCLONAL PROTEINS AND RENAL DISEASE. <i>Annual Review of Medicine</i> , 1994, 45, 71-77.	5.0	35
148	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 775-790.	0.9	35
149	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
150	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
151	MASSiFiX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. <i>American Journal of Hematology</i> , 2018, 93, E368-E370.	2.0	34
152	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
153	Porphyria Cutanea Tarda Associated with Chronic Granulocytic Leukemia Treated with Busulfan (Myleran). <i>Blood</i> , 1964, 23, 776-785.	0.6	32
154	IgD monoclonal gammopathy with long-term follow-up. <i>British Journal of Haematology</i> , 1994, 88, 395-396.	1.2	32
155	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	2.0	32
156	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
157	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
158	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	0.6	31
159	Monoclonal gammopathies of undetermined significance. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 689-707.	0.7	31
160	Soluble suppression of tumorigenicity 2 (sTSG2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
161	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. <i>British Journal of Haematology</i> , 1995, 90, 459-461.	1.2	30
162	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30

#	ARTICLE	IF	CITATIONS
163	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
164	Synovial fluid analysis for diagnosis of amyloid arthropathy. <i>Arthritis and Rheumatism</i> , 1987, 30, 419-423.	6.7	29
165	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
166	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
167	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
168	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
169	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
170	IgD multiple myeloma: A cure at 21 years. <i>American Journal of Hematology</i> , 1988, 29, 41-43.	2.0	26
171	MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 225-252.	0.1	26
172	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
173	Localized AL amyloidosis of the colon: an unrecognized entity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 36-41.	1.4	25
174	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
175	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
176	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
177	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
178	A monoclonal antibody reactive with a subset of human plasma cells. <i>British Journal of Haematology</i> , 1986, 62, 619-630.	1.2	24
179	Prognostic factors in multiple myeloma. <i>Hematological Oncology</i> , 1988, 6, 125-130.	0.8	24
180	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	0.2	24

#	ARTICLE	IF	CITATIONS
181	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
182	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
183	Immunoperoxidase staining of bone marrow sections. <i>Cancer</i> , 1981, 48, 2438-2446.	2.0	23
184	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.1	23
185	Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1937-1943.	2.4	23
186	IgG Subclasses: Relationship to Clinical Aspects of Multiple Myeloma and Frequency Distribution among M-components. <i>Scandinavian Journal of Haematology</i> , 1974, 12, 60-68.	0.0	22
187	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.4	22
188	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
189	Update on the Treatment of Multiple Myeloma. <i>Oncologist</i> , 2001, 6, 119-124.	1.9	21
190	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
191	Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
192	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
193	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 181-187.	1.0	20
194	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20
195	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
196	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019, 184, 1014-1017.	1.2	20
197	Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. <i>American Journal of Hematology</i> , 1989, 32, 226-229.	2.0	19
198	Henry Bence Jones - physician, chemist, scientist and biographer: A man for all seasons. <i>British Journal of Haematology</i> , 2001, 115, 13-18.	1.2	19



#	ARTICLE	IF	CITATIONS
217	Primary amyloidosis (AL) in families. American Journal of Hematology, 1986, 22, 193-198.	2.0	14
218	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. British Journal of Haematology, 1998, 100, 326-327.	1.2	14
219	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	2.0	14
220	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14
221	Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. , 1997, 9, 83-85.		13
222	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	2.0	13
223	History of Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 3-23.	1.8	13
224	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer Journal, 2022, 12, 67.	2.8	13
225	Current Therapy of Multiple Myeloma.. Internal Medicine, 2002, 41, 175-180.	0.3	12
226	Prognostic factors and indications for treatment of WaldenstrÃ¶m's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 179-186.	0.7	12
227	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	1.2	12
228	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	3.3	12
229	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	2.8	12
230	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	2.0	12
231	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	1.4	12
232	Assessment of fixedâ€duration therapies for treatmentâ€naïve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
233	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
234	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	0.6	12

#	ARTICLE	IF	CITATIONS
235	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.	3.3	12
236	Amyloidosis: Part 1. <i>International Journal of Dermatology</i> , 1980, 19, 537-539.	0.5	11
237	Speech disorders in systemic amyloidosis. <i>International Journal of Language and Communication Disorders</i> , 1991, 26, 201-206.	0.7	11
238	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. <i>Leukemia and Lymphoma</i> , 2000, 39, 391-395.	0.6	11
239	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
240	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
241	John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library. <i>Mayo Clinic Proceedings</i> , 2019, 94, e45-e46.	1.4	11
242	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. <i>Blood Cancer Journal</i> , 2019, 9, 49.	2.8	11
243	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
244	Amyloidosis:. <i>International Journal of Dermatology</i> , 1981, 20, 75-80.	0.5	10
245	Role of Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma: Lessons for Cancer Therapy. <i>Mayo Clinic Proceedings</i> , 2011, 86, 419-420.	1.4	10
246	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017, 179, 170-172.	1.2	10
247	A role for bone turnover markers $\beta$ <sup>2</sup> -CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2431-2438.	0.6	10
248	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021, 11, 26.	2.8	10
249	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 70-75.	1.1	9
250	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and $\beta$ <sup>2</sup> interferon versus VBMCP. <i>Cancer</i> , 2009, 115, 2155-2164.	2.0	9
251	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
252	Risk of melanoma in patients with multiple myeloma: A Surveillance, Epidemiology, and End Results population-based study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 621-623.	0.6	9

#	ARTICLE	IF	CITATIONS
253	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	1.4	9
254	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia, 2019, 33, 499-507.	3.3	9
255	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.2	9
256	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	2.8	9
257	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. Blood, 2005, 106, 3396-3396.	0.6	9
258	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	0.8	9
259	Serial Studies of Peripheral Blood Myeloma Cells in Patients with Multiple Myeloma: When is the Optimal Time for Stem Cell Harvest?. Leukemia and Lymphoma, 1995, 19, 417-422.	0.6	8
260	Primary plasmacytoma at the site of exit wounds after electrical injury. , 1998, 58, 77-79.		8
261	Targeted therapy of multiple myeloma. Hematology, 2012, 17, s125-s128.	0.7	8
262	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. JAMA Oncology, 2015, 1, 174.	3.4	8
263	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
264	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
265	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	2.8	8
266	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	3.3	8
267	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
268	Diagnosis of multiple myeloma. Seminars in Oncology, 2002, 29, 2-4.	0.8	8
269	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	2.8	8
270	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	0.6	8



#	ARTICLE	IF	CITATIONS
271	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio $\geq 100$ . <i>Leukemia</i> , 2022, 36, 1429-1431.	3.3	8
272	Familial amyloid with a transthyretin leucine 33 mutation presenting with ascites. , 1998, 59, 249-251.		7
273	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
274	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
275	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954.	1.4	7
276	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	0.6	7
277	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428.	3.3	7
278	Alexandre Yersin: Discoverer of the Plague Bacillus. <i>Mayo Clinic Proceedings</i> , 2020, 95, e7-e8.	1.4	6
279	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6
280	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenström's Macroglobulinemia. <i>Blood</i> , 2008, 112, 2709-2709.	0.6	6
281	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
282	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017, 92, E164-E166.	2.0	5
283	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
284	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
285	Andreas Vesalius and De Fabrica. <i>Mayo Clinic Proceedings</i> , 2019, 94, e67-e68.	1.4	5
286	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
287	James Till and Ernest McCulloch: Hematopoietic Stem Cell Discoverers. <i>Mayo Clinic Proceedings</i> , 2021, 96, 830-831.	1.4	5
288	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2005, 106, 781-781.	0.6	5

#	ARTICLE	IF	CITATIONS
289	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
290	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5
291	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997, 90, 340-345.	0.6	5
292	Multiple Myeloma: An Overview in 1996. <i>Oncologist</i> , 1996, 1, 315-323.	1.9	5
293	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	2.0	5
294	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
295	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
296	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	1.4	4
297	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
298	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
299	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
300	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
301	Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. <i>Redox Biology</i> , 2021, 41, 101927.	3.9	4
302	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , 2021, 97, 67-73.	0.8	4
303	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
304	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
305	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	0.6	4
306	IgG Cryoglobulinemia Associated With Amyloidosis. <i>Blood</i> , 1973, 41, 569-576.	0.6	3

#	ARTICLE	IF	CITATIONS
307	Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 1994, 87, 719-724.	1.2	3
308	Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2160.	3.8	3
309	Reply to Castillo et al.. <i>American Journal of Hematology</i> , 2018, 93, E71-E73.	2.0	3
310	Serum free light chain measurements to reduce 24-hr urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3
311	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
312	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
313	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	0.6	3
314	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
315	Primary systemic amyloidosis with delayed progression to multiple myeloma. , 1998, 82, 1501.		3
316	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
317	Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials. <i>Blood</i> , 2008, 112, 5129-5129.	0.6	3
318	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008, 112, 95-95.	0.6	3
319	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3981-3981.	0.6	3
320	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. <i>Blood</i> , 2013, 122, 2136-2136.	0.6	3
321	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 3119-3119.	0.6	3
322	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	0.6	3
323	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8004-8004.	0.8	3
324	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	0.6	3

#	ARTICLE	IF	CITATIONS
325	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.	3.3	3
326	Multiple myeloma: an odyssey of discovery. <i>British Journal of Haematology</i> , 2000, 111, 1035-1044.	1.2	2
327	Albert Schweitzer: Humanitarian With a "Reverence for Life". <i>Mayo Clinic Proceedings</i> , 2019, 94, e91-e92.	1.4	2
328	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
329	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
330	Albin Lambotte: Pioneer of Osteosynthesis (Bone Fixation). <i>Mayo Clinic Proceedings</i> , 2021, 96, 2012-2013.	1.4	2
331	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
332	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
333	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
334	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
335	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	0.6	2
336	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
337	Daratumumab-based therapies in patients with AL amyloidosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8053-8053.	0.8	2
338	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. <i>Blood</i> , 2005, 106, 1545-1545.	0.6	2
339	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. <i>Blood</i> , 2012, 120, 1861-1861.	0.6	2
340	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
341	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
342	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	2.0	2

#	ARTICLE	IF	CITATIONS
343	The definition of IgM multiple myeloma. American Journal of Hematology, 2011, 86, 718-719.	2.0	1
344	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	1.4	1
345	Luke Fildes and The Doctor. Mayo Clinic Proceedings, 2019, 94, e131-e132.	1.4	1
346	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	0.8	1
347	Emile Letournel: Pioneer of Acetabular Surgery. Mayo Clinic Proceedings, 2021, 96, 1379-1380.	1.4	1
348	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
349	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	0.6	1
350	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	0.6	1
351	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	0.6	1
352	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. Blood, 2007, 110, 2477-2477.	0.6	1
353	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	0.6	1
354	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	0.6	1
355	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	0.6	1
356	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	0.6	1
357	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	0.6	1
358	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	0.6	1
359	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	0.6	1
360	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. Journal of Clinical Oncology, 2016, 34, 8015-8015.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, 8038-8038.	0.8	1
362	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	0.8	1
363	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	0.6	1
364	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. Blood, 2006, 108, 3493-3493.	0.6	1
365	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.	0.8	1
366	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.	0.6	1
367	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	0.8	1
368	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
369	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
370	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
371	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
372	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	0.6	1
373	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	0.6	1
374	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	0.6	1
375	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	0.6	1
376	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	0.6	1
377	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	0.6	1
378	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). Blood, 2020, 136, 40-41.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
380	VIII International Symposium on Amyloidosis, August 7-11,1998, Rochester, MN. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 59-62.	1.4	0
381	POEMS Syndrome. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 186.	2.1	0
382	Fernando Figueira: Brazilian Public Health Champion. <i>Mayo Clinic Proceedings</i> , 2020, 95, e97-e98.	1.4	0
383	Roald Dahl: Children's Book Author, Medical Device Inventor, Myelodysplastic Syndrome Patient, and Philanthropist. <i>Mayo Clinic Proceedings</i> , 2020, 95, e119-e120.	1.4	0
384	Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology. <i>Mayo Clinic Proceedings</i> , 2020, 95, e53-e54.	1.4	0
385	Recognizing "diagnostic futility" - stopping earlier to protect patients. <i>American Journal of Hematology</i> , 2020, 95, 580-582.	2.0	0
386	Kaare Nygaard: Surgeon, Scientist, Sculptor. <i>Mayo Clinic Proceedings</i> , 2021, 96, e7-e8.	1.4	0
387	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	0.8	0
388	Dr John H. Watson: Sherlock Holmes's™ Companion and Biographer. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2500-2502.	1.4	0
389	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. <i>Blood</i> , 2004, 104, 1475-1475.	0.6	0
390	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. <i>Blood</i> , 2004, 104, 928-928.	0.6	0
391	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. <i>Blood</i> , 2004, 104, 1493-1493.	0.6	0
392	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. <i>Blood</i> , 2005, 106, 3381-3381.	0.6	0
393	Response to Rituximab in Type II Cryoglobulinemia.. <i>Blood</i> , 2005, 106, 3499-3499.	0.6	0
394	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. <i>Blood</i> , 2006, 108, 3587-3587.	0.6	0
395	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. <i>Blood</i> , 2007, 110, 4778-4778.	0.6	0
396	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1492-1492.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	0.6	0
398	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. Blood, 2007, 110, 4779-4779.	0.6	0
399	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. Blood, 2008, 112, 1672-1672.	0.6	0
400	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. Blood, 2008, 112, 1707-1707.	0.6	0
401	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	0.6	0
402	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. Blood, 2012, 120, 934-934.	0.6	0
403	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. Blood, 2012, 120, 2059-2059.	0.6	0
404	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	0.6	0
405	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	0.6	0
406	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	0.6	0
407	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	0.6	0
408	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	0.6	0
409	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. Journal of Clinical Oncology, 2016, 34, 8035-8035.	0.8	0
410	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.	0.8	0
411	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.	0.8	0
412	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0
413	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	0.6	0
414	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	0.6	0



#	ARTICLE	IF	CITATIONS
415	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
416	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
417	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	0.6	0
418	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	0.6	0
419	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	0.6	0
420	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
421	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
422	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19530-e19530.	0.8	0
423	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8049-8049.	0.8	0
424	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8047-8047.	0.8	0
425	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532.	0.8	0
426	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8032-8032.	0.8	0
427	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8023-8023.	0.8	0
428	Natural history of del53 multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20017-e20017.	0.8	0
429	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7571-7571.	0.8	0
430	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8045-8045.	0.8	0
431	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8030-8030.	0.8	0
432	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018, 132, 1912-1912.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
434	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
435	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
436	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
437	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
438	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
439	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
440	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
441	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0
442	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	0.6	0
443	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0
444	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	0.6	0
445	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	0.6	0
446	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
447	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	0.6	0
448	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	0.6	0
449	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	0.6	0
450	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
452	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
453	M. Vera Peters: Pioneering Radiation Oncologist. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2927-2928.	1.4	0
454	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0
455	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFN $\beta$ -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
456	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
457	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio $\geq 100$ . <i>Blood</i> , 2021, 138, 1617-1617.	0.6	0
458	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.	0.6	0
459	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021, 138, 3773-3773.	0.6	0
460	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.	0.6	0
461	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 1632-1632.	0.6	0
462	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1619-1619.	0.6	0
463	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543.	0.6	0
464	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021, 138, 1630-1630.	0.6	0
465	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021, 138, 119-119.	0.6	0
466	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650.	0.6	0
467	Suzanne Gros NoÅ«l: Plastic Surgery Pioneer and Advocate for Womenâ€™s Rights. <i>Mayo Clinic Proceedings</i> , 2022, 97, 196-197.	1.4	0
468	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	0.6	0

#	ARTICLE	IF	CITATIONS
469	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	0.6	0
470	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
471	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
472	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
473	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0
474	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. Blood, 2020, 136, 15-16.	0.6	0
475	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
476	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
477	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0
478	Samuel Gridley Howe: Abolitionist, Physician, and Pioneer in Education of Children With Vision Loss and Mental Disability. Mayo Clinic Proceedings, 2022, 97, 633-635.	1.4	0
479	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
480	Commercial Advertising on Postage Stamps: The Curious Case of Dr Francis Macbean Stewart's Miracle Cure. Mayo Clinic Proceedings, 2022, 97, 1029-1032.	1.4	0
481	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	0.8	0
482	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e19562-e19562.	0.8	0